Navigation Links
LifeCell Corporation Revises Full Year 2007 Preliminary Results and Schedules Fourth Quarter 2007 Financial Results Conference Call; February 27, 2008 at 10:00 a.m. Eastern
Date:2/7/2008

BRANCHBURG, N.J., Feb. 7 /PRNewswire-FirstCall/ -- LifeCell Corporation (Nasdaq: LIFC), today announced revised preliminary full-year 2007 diluted net income per share due to the final settlement of a claim that arose in 2007. The claim, which was not product related, is expected to reduce diluted net income per share by approximately $0.03. "Although the final resolution of the claim occurred in 2008, since the Company's 2007 financial statements were not yet filed with the Securities and Exchange Commission, we are required to report the amount as a fourth quarter 2007 item," stated Steven Sobieski, LifeCell's Chief Financial Officer. The Company now anticipates full-year 2007 diluted net income per share to be in the range $0.77 to $0.78 compared to the previously announced range of $0.80 to $0.82. The change in estimate is entirely related to the settlement.

The Company also announced that it plans to release fourth quarter and full year 2007 actual operating results on Wednesday, February 27, 2008 at 8:00 a.m. Eastern. Paul Thomas, President and Chief Executive Officer, will host a conference call at 10:00 a.m. Eastern, to discuss the Company's fourth quarter and full year 2007 financial results.

The dial-in number for the call is (877) 419-6590/domestic or (719) 325- 4855/international. A simultaneous webcast of the call will be available via LifeCell's website at http://www.lifecell.com Corporate Information - Investor Relations. The call will be archived on the Company's website for at least 90 days.

A recording of the live-call will be available through March 6, 2008. The dial-in number to listen to the recording is (888) 203-1112 or (719) 457-0820. The replay access code is 4743271.

About LifeCell

LifeCell is the leading provider of innovative biological products for soft tissue repair. Surgeons use our products to restore structure, function and physiology in a variety of reconstructive, orthopedic and urogynecologic surgical procedures. LifeCell's products include: ALLODERM(R) regenerative tissue matrix, for plastic reconstructive, general surgical, burn and periodontal procedures; STRATTICE(TM) reconstructive tissue matrix, for plastic reconstructive and general surgical procedures; GRAFTJACKET(R) regenerative tissue matrix, for orthopedic applications and lower extremity wounds; ALLOCRAFT(R)DBM, for bone grafting procedures; and REPLIFORM(R) tissue regeneration matrix for urogynecologic surgical procedures. The Company's research and development initiatives include programs designed to extend the use of its current marketed products into new surgical applications as well as expanding its product line in the rapidly growing biosurgery market. LifeCell maintains a website at http://www.lifecell.com.


'/>"/>
SOURCE LifeCell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. LifeCell Corporation Schedules Third Quarter 2007 Financial Results Conference Call; October 25, 2007 at 10:00 A.M. Eastern
2. LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern
3. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
6. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
7. BioElectronics Corporation Announces Singapore and Malaysia Sales
8. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
9. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
10. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
11. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):